Human Microbiome Market – Snapshot
The human microbiome market
exhibits significant potential in the near future due to huge untapped
medical needs. The market is set to create lucrative opportunities due
to a large number of ongoing clinical trials and entry of new players in
the market. Presently, the human microbiome market is in the nascent
stage, and therapies are still in the pre-clinical and clinical stage.
Diagnostics is also in the development phase of the product life cycle.
In November 2016, uBiome launched the SmartGut test for diagnosis of gut
health disorders. Companies have begun to allocate significant funds
for research and development and management of clinical studies for
innovative therapies.
Lack of targeted drugs in the market for specific
conditions, such as C.difficile infection and ulcerative colitis, makes
it a highly opportune condition for players to set their innovative drug
ideas on the path of commercial success. The human microbiome comprises
genetic material within a microbiota (the entire collection of
microorganisms, such as bacteria, virus, fungi, archea, etc. in specific
areas of the human body, such as the gut, vagina, oral cavity, etc.).
The human microbiome market is driven by factors, such as rise in
clinical trials for gut health-based diseases and increase in funds by
investors or venture capital firms/individual venture capitalists for
research and development on human microbiome-based therapies. However,
the present lack of certainty in the performance of these drugs in the
long-run and regulatory hurdles are anticipated to restrain the growth
of the market during the forecast period. Nevertheless, the human
microbiome diagnostics market is anticipated to be driven by rising
preference of patients for descriptive, rapid, and non-invasive
sequencing-based microbiome tests for diseases such as colon cancer,
vaginosis, and Crohn’s disease.
The global human microbiome diagnostics
market is projected to expand at a robust CAGR of 9.8% during the
forecast period, i.e. between 2018 and 2026, while the human microbiome
therapeutics market is likely show similar exceptional growth with a
CAGR of 9.6% during the forecast period from 2020 to 2026. Driven by
huge unmet clinical needs for disease management and rising research and
development expenditure; the global human microbiome diagnostics market
is anticipated to be valued at US$ 892.1 Mn in 2018. It is expected to
reach a value of US$ 1,888.9 Mn by 2026, reflecting a CAGR of 9.8%,
while the global human microbiome therapeutics market is anticipated to
be valued at US$ 1,245.3 Mn in 2020. It is expected to reach a value of
US$ 2,160.9 Mn by 2026, registering a CAGR of 9.6%.
Based on therapeutic area, the human
microbiome therapeutics market has been segmented into gastrointestinal
disorders, metabolic disorders, women’s health, skin disorders, and
others. The others segment includes therapeutic areas for infant health,
infections and autoimmune diseases, and rare diseases. The
gastrointestinal disorders segment is likely to capture the leading
position in the market and exhibit high attractiveness due to the
presence of a large number of therapies under clinical trials directed
toward treating gastrointestinal disturbances, coupled with the existing
unmet medical needs in gut health concerns. According to the CDC, on
the basis of a study conducted in 2015, in the U.S., approximately 1 out
of every 11 patients, over 65 years of age with C. difficile, dies
within 30 days of diagnosis, which is an alarming figure. The CDC also
estimated that about one of five patients had a recurrence of the
illness. Thus, therapies such as SER-109, targeted toward the prevention
of recurrent clostridium difficile infection (CDI) has shown promising
results in clinical trials with less reoccurrence rate. This provides
lucrative opportunities during the forecast period. The gastrointestinal
diseases segment is likely to capture over 59.7% of the global human
microbiome therapeutics market in 2020.
The global human microbiome diagnostics
market has been segmented on the basis of indication, technology, and
region. The gastrointestinal and metabolic disorders segments are
projected to exhibit a total incremental opportunity of US$ 586.9 Mn
from 2018 to 2026. Launch of tests aimed at diagnosing gut health
imbalances and disorders, such as SmartGut by uBiome, is likely to
propel the segment during the forecast period.
Key companies profiled in the report
include AOBiome LLC, Osel, Inc., Seres Therapeutics, Second Genome,
uBiome, Inc., Metabiomics Corp., Rebiotix, Inc., Vedanta Biosciences,
Enterome, Biosciences, and Synthetic Biologics, Inc.
No comments:
Post a Comment